Abstract
Objective
To report real-world 6- and 12-month outcomes in children with growth hormone deficiency (GHD) treated with somatrogon or somatropin, including those who transitioned from somatropin to somatrogon.
Methods
Eligible patients were categorized into three groups [somatrogon-naïve (naïve), somatrogon-switch (switch), and somatropin only] and were followed for 6 or 12 months. Bioimpedance analysis, as well as a standardized, age-appropriate assessment of the Pediatric Quality of Life Inventory (PedsQL), the Child Behavioural Checklist (CBCL) and the Multidimensional Scale of Perceived Social Support (MSPSS), were conducted at baseline and month 6 in the naïve and switch groups. Psychiatric evaluations were also performed according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria.
Results
A total of 58 patients (58.6% male) were included (naïve: n=20; switch: n=18; somatropin: n=20). Mean ages were 11.1±3.0, 9.7±3.4, and 10.5±3.2 years, respectively. After 12 months, mean changes in height standard deviation score (Δheight SDS) were 0.6±0.3, 0.7±0.3, and 0.7±0.4; and height velocities were 10.0±1.9, 9.1±1.7, and 9.8±1.9 cm/year, respectively. Corresponding increases in IGF-1 SDS (ΔIGF-1 SDS) were 2.2±1.2, 0.9±1.2, and 1.3±1.0, respectively. Among the 38 patients receiving somatrogon, 15.8% (n=6; 3 naïve, 3 switch) developed IGF-1 SDS >+2 during follow-up, managed successfully with observation or dose adjustment. No serious adverse events were observed. Bioimpedance analyses demonstrated a favorable but non-significant trend toward improved body composition in somatrogon-naïve children. At six months, PedsQL domains, CBCL scales, and MSPSS scores remained stable (all p>0.05).
Conclusion
Once-weekly somatrogon demonstrated efficacy and safety comparable to daily somatropin with stable quality-of-life and psychosocial outcomes in children with GHD.
Keywords: Children, growth hormone, growth hormone deficiency, long-acting growth hormone
Read the full text
5 sections · 4 figures · 3 tables · PDF
Create your free account to read the full text.
- Full text with figures and tables
- PDF and supplementary files
- Access on every Galenos journal
One Galenos account works on every Galenos journal site.
References
Loftus J, Quitmann J, Valluri SR. Health-related quality of life in pre-pubertal children with pediatric growth hormone deficiency: 12-month results from a phase 3 clinical trial of once-weekly somatrogon versus once-daily somatropin. Curr Med Res Opin. 2024;40:175-184. Epub 2024 Jan 24
Rothermel J, Reinehr T. Metabolic alterations in paediatric GH deficiency. Best Pract Res Clin Endocrinol Metab. 2016;30:757-770. Epub 2016 Nov 4
Şengün D, Çayır A. The effects of growth hormone treatment in patients with isolated growth hormone deficiency on hematological parameters. Trends in Pediatrics. 2021;2:165-169.
Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M, Kim HS, Ko C, Malievskiy O, Cara JF, Roland CL, Taylor CT, Valluri SR, Wajnrajch MP, Pastrak A, Miller BS. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab. 2022;107:e2717-e2728.
González Briceño LG, Viaud M, Beltrand J, Flechtner I, Dassa Y, Samara-Boustani D, Thalassinos C, Pauwels C, Busiah K, Pinto G, Jaquet D, Polak M. Improved general and height-specific quality of life in children with short stature after 1 year on growth hormone. J Clin Endocrinol Metab. 2019;104:2103-2111.
Quitmann J, Bloemeke J, Silva N, Bullinger M, Witt S, Akkurt I, Dunstheimer D, Vogel C, Böttcher V, Kuhnle Krahl U, Bettendorf M, Schönau E, Fricke-Otto S, Keller A, Mohnike K, Dörr HG. Quality of life of short-Statured children born small for gestational age or idiopathic growth hormone deficiency within 1 year of growth hormone treatment. Front Pediatr. 2019;7:164.
Graham S, Weinman J, Auyeung V. Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: a systematic review. Horm Res Paediatr. 2018;90:221-227. Epub 2018 Dec 6
Mameli C, Orso M, Calcaterra V, Wasniewska MG, Aversa T, Granato S, Bruschini P, Guadagni L, d’Angela D, Spandonaro F, Polistena B, Zuccotti G. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: a systematic review and meta-analysis. Pharmacol Res. 2023;193:106805. Epub 2023 May 24
Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291-303.
Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child. 1970;45:13-23.
Demir K, Özen S, Konakçı E, Aydın M, Darendeliler F. A Comprehensive Online Calculator for Pediatric Endocrinologists: ÇEDD Çözüm/TPEDS Metrics. J Clin Res Pediatr Endocrinol. 2017;9:182-184. Epub 2017 Apr 26
Demir K, Konakçı E, Özkaya G, Kasap Demir B, Özen S, Aydın M, Darendeliler F. New Features for child metrics: further growth references and blood pressure calculations. J Clin Res Pediatr Endocrinol. 2020;12:125-129. Epub 2019 Sep 2
Greulich WW, Pyle SJ. Radiographic atlas of skeletal development of the hand and wrist. 1st ed. Stanford, CA: Stanford University Press; 1959;1-272.
BoneXpert. Bone age software. Available from: http://software.ddp.org.nz/bone-age/. Accessed September 7, 2025.
Nayak S, Wajnrajch MP, Korth-Bradley J, Taylor CT, Thomas M, Maniatis A, Deal CL, Rosenfeld RG, Cara JF, Ravva P. IGF-1 Assessment during weekly somatrogon treatment in pediatric patients with GH deficiency. J Endocr Soc. 2025;9:bvaf001.
Varni JW, Seid M, Rode CA. The PedsQL: measurement model for the pediatric quality of life inventory. Med Care. 1999;37:126-139.
Çakın Memik N, Ağaoğlu B, Coşkun A. The validity and reliability of the Turkish pediatric quality of life inventory for children 13-18 years old. Türk Psikiyatri Dergisi. 2007;18:353-363.
Achenbach TM, Edelbrock C, Howell CT. Empirically based assessment of the behavioral/emotional problems of 2- and 3- year-old children. J Abnorm Child Psychol. 1987;15:629-650.
Erol N, Simsek Z, Oner O, Munir K. Behavioral and emotional problems among Turkish children at ages 2 to 3 years. J Am Acad Child Adolesc Psychiatry. 2005;44:80-87.
Zimet GD, Dahlem NW, Zimet SG, Farley GK. The multidimensional scale of perceived social support. J Pers Assess. 1988;52:30-41.
Eker D, Arkar H. Çok boyutlu algılanan sosyal destek ölçeği’nin faktör yapısı, geçerlik ve güvenirliği. Türk Psikoloji Dergisi. 1995b;34:45-55.
Horikawa R, Tanaka T, Hasegawa Y, Yorifuji T, Ng D, Rosenfeld RG, Hoshino Y, Okayama A, Shima D, Gomez R, Pastrak A, Castellanos O. Efficacy and safety of once-weekly somatrogon compared with once-daily somatropin (Genotropin®) in Japanese children with pediatric growth hormone deficiency: results from a randomized phase 3 study. Horm Res Paediatr. 2022;95:275-285. Epub 2022 Apr 13
Zadik Z, Zelinska N, Iotova V, Skorodok Y, Malievsky O, Mauras N, Valluri S, Pastrak A, Rosenfeld R. An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment. Journal of Pediatric Endocrinology and Metabolism. 2023;36:261-269.
Çetinkaya S, Eren E, Erdoğan F, Darendeliler F. Rationale for long-acting growth hormone therapy and future aspects. J Clin Res Pediatr Endocrinol. 2025;17:1-8. Epub 2024 Mar 15
Maniatis AK, Wajnrajch MP, Thomas M, Chung SB, Lee J. Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations. Ann Pediatr Endocrinol Metab. 2025;30:11-16. Epub 2025 Feb 28
Andreu Crespo MA, Castro-Feijóo L, Labarta-Aizpún JI, Peral C, Barrueta JA, Rubio-Rodríguez D, Rubio-Terres C. Cost-effectiveness of somatrogon in the Spanish pediatric population with growth hormone deficiency. Expert Rev Pharmacoecon Outcomes Res. 2023;23:1139-1146. Epub 2023 Nov 13
Gomez R, Lamoureux R, Turner-Bowker DM, Loftus J, Maghnie M, Miller BS, Polak M, Yaworsky A. Physician experience with once-weekly somatrogon versus once-daily rhGH regimen in pediatric patients with growth hormone deficiency: a cross-sectional survey of physicians from the global phase 3 study. Front Endocrinol (Lausanne). 2023;14:1254424.
Zelinska N, Iotova V, Skorodok J, Malievsky O, Peterkova V, Samsonova L, Rosenfeld RG, Zadik Z, Jaron-Mendelson M, Koren R, Amitzi L, Raduk D, Hershkovitz O, Hart G. Long-acting C-terminal peptide–modified hGH (MOD-4023): results of a safety and dose-finding study in GHD children. J Clin Endocrinol Metab. 2017;102:1578-1587.
Chhiba PD, Segal D. Lipoatrophy associated with daily growth hormone injections. Endocrinol Diabetes Metab Case Rep. 2021;2021:21-0087.
Büyükgebiz A, Demir A. Severe lipoatrophy in a growth hormone deficient toddler girl treated with a non-pegylated long-acting growth hormone. Children (Basel). 2025;12:58.
Maniatis AK, Carakushansky M, Galcheva S, Prakasam G, Fox LA, Dankovcikova A, Loftus J, Palladino AA, de Los Angeles Resa M, Turich Taylor C, Dattani MT, Lebl J. Treatment burden of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a randomized study. J Endocr Soc. 2022;6:bvac117.
